Knowing your ABCCs: Novel functions of ABCC transporters

Journal of the National Cancer Institute

Volumn 103, Issue 16, 2011, Pages 1207-1208

  Brodeur, Garrett M ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN ABCC; PROTEIN ABCC1; PROTEIN ABCC3; PROTEIN ABCC4; UNCLASSIFIED DRUG;

CANCER PATIENT; CELL MIGRATION; CELL PROLIFERATION; EDITORIAL; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; NEUROBLASTOMA; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEUROBLASTOMA; PYRAZOLES; PYRIMIDINES;

EID: 80052010940     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr277     Document Type: Editorial

References (27)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203-216. (Pubitemid 37328872)
2. Brodeur GM, Hogarty MD, Mosse YP, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2011:886-922.
3. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106-2120. (Pubitemid 46935947)
4. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353(21):2243-2253. (Pubitemid 41697287)
5. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999;340(25):1954-1961. (Pubitemid 29288271)
6. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol. 1995;24(4):215-221.
7. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1996;334(4):225-230. (Pubitemid 26030673)
8. Guo C, White PS, Weiss MJ, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene. 1999;18(35):4948-4957. (Pubitemid 29425301)
9. Maris JM, Weiss MJ, Guo C, et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol. 2000;18(9):1888-1899. (Pubitemid 30261926)
10. Maris JM, White PS, Beltinger CP, et al. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res. 1995;55(20):4664-4669.
11. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121-1124. (Pubitemid 14106392)
12. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313(18):1111-1116. (Pubitemid 16216827)
13. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991;9(4):581-591.
14. George RE, London WB, Cohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 2005;23(27):6466-6473. (Pubitemid 46190237)
15. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 1984;311(4):231-235. (Pubitemid 14087665)
16. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27(2):298-303.
17. Gillet JP, Gottesman MM. Mechanisms of Multidrug resistance in cancer. Methods Mol Biol. 2010;596:47-76.
18. Haber M, Smith J, Bordow SB, et al. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol. 2006;24(10):1546-1553. (Pubitemid 46638777)
19. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med. 1996;334(4): 231-238. (Pubitemid 26032215)
20. Dhooge CR, De Moerloose BM, Benoit YC, Van Roy N, Philippe J, Laureys GG. Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma. Cancer. 1997;80(7):1250-1257. (Pubitemid 27407225)
21. Haber M, Bordow SB, Haber PS, Marshall GM, Stewart BW, Norris MD. The prognostic value of MDR1 gene expression in primary untreated neuroblastoma. Eur J Cancer. 1997;33(12):2031-2036. (Pubitemid 28123449)
22. Qiu YY, Mirkin BL, Dwivedi RS. MDR1 hypermethylation contributes to the progression of neuroblastoma. Mol Cell Biochem. 2007;301(1-2): 131-135. (Pubitemid 46895153)
23. Henderson MJ, Haber M, Porro A, et al. ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst. 2011;103(16):1236-1251.
24. Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer. 2010;10(2): 147-156.
25. Ross RA, Spengler BA, Biedler JL. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst. 1983;71(4):741-747. (Pubitemid 14232388)
26. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997;16(11):2985-2995. (Pubitemid 27234938)
27. Zhou SF, Wang LL, Di YM, et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem. 2008;15(20):1981-2039.